| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/06/2004 | EP0971945B1 Method for preparation of conjugate vaccines using uronium salt |
| 10/06/2004 | EP0971739B1 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| 10/06/2004 | EP0941240B1 New picornaviruses, vaccines and diagnostic kits |
| 10/06/2004 | EP0876498B1 Mixture of recombinant vaccinia vectors as polygeur vaccines for hiv |
| 10/06/2004 | CN1535314A Homologous 28-kilodalton immunodominant protein genes of Ehrlichia canis and uses thereof |
| 10/06/2004 | CN1535282A Ganalioside-associated recombinant antibodies and use thereof in diagnosis and treatment of tumours |
| 10/06/2004 | CN1535160A Use of IL-18 inhibitors for treating or preventing CNS injuries |
| 10/06/2004 | CN1535159A Medicine box containing anti human spermatine single chain antibody/human carboxypeptidase A fusion progein and precusor medicine |
| 10/06/2004 | CN1535158A Vaccines comprising aluminium adjuvants and histidine |
| 10/06/2004 | CN1535157A West nile vaccine |
| 10/06/2004 | CN1535151A Novel anti-infectives |
| 10/06/2004 | CN1535140A Microparticle compositions and method for manufacture thereof |
| 10/06/2004 | CN1534092A Colibacillus containing human source guide suppository dissolving antibody gene and its secretion producg |
| 10/06/2004 | CN1533808A Composition for treating coronavirus infection and SARS and method |
| 10/06/2004 | CN1169966C Isolated, tyrosinase derived peptides and uses thereof |
| 10/06/2004 | CN1169952C Heavy chain and light chain variable region gene of anti-CD 20 monoclonal antibody and its application |
| 10/06/2004 | CN1169837C Double specific monoclonal anti-body, its preparing method and thromobolysin made therefrom |
| 10/05/2004 | US6800746 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 10/05/2004 | US6800740 Variants of native growth hormones having non naturally occurring amino acid sequences or covalent modifications |
| 10/05/2004 | US6800737 Amino acid sequences; anticaner agents, monitoring, diagnosis |
| 10/05/2004 | US6800734 Membrane proteins, such as kinase, permease, mannosyltransferase and endoflagellin used to induce a protective immune response in animals; vaccines |
| 10/05/2004 | US6800730 Such as tumor rejection antigens which bind human leukocyte antigen which provokes proliferation of cd4 cells; immunotherapy; anticarcinogenic agents; stimulation of cytotoxic t-cells |
| 10/05/2004 | US6800609 Isolated peptide of the horny layer and user thereof |
| 10/05/2004 | US6800483 Compositions and methods for sensitizing and inhibiting growth of human tumor cells |
| 10/05/2004 | US6800469 Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens |
| 10/05/2004 | US6800441 Heparanase specific molecular probes and their use in research and medical applications |
| 10/05/2004 | US6800289 Strain of the western equine encephalitis virus |
| 10/05/2004 | US6800288 Recombinant ns gene of influenza a virus comprising a functional rna binding domain and a sequence modification of the ns1 gene segment which bars transcription of the remaining portion of that segment; vaccines |
| 10/05/2004 | US6800285 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 10/05/2004 | CA2128833C P53as protein and antibody therefor |
| 10/04/2004 | CA2463115A1 Anti-inflammatory composition |
| 09/30/2004 | WO2004083397A2 Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv |
| 09/30/2004 | WO2004083392A2 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
| 09/30/2004 | WO2004083382A2 Compositions and methods for treating hyperimmune response in the eye |
| 09/30/2004 | WO2004083375A2 Methods of promoting the differentiation of stem cells |
| 09/30/2004 | WO2004083374A2 Methods for screening for an antigen for use in a vaccine |
| 09/30/2004 | WO2004083372A2 Modulators of the notch signaling pathway immobilized on particles for modifying immune responses |
| 09/30/2004 | WO2004083251A2 Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| 09/30/2004 | WO2004082712A1 Bivalent vaccine |
| 09/30/2004 | WO2004082711A1 Inactivated vibrio cholerae vaccine in tablet form |
| 09/30/2004 | WO2004082710A1 Treatment of allergic diseases using a modulator of the notch signaling pathway |
| 09/30/2004 | WO2004082640A2 Human serum albumin conjugates with therapeutic compounds |
| 09/30/2004 | WO2004082569A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3) |
| 09/30/2004 | WO2004082568A2 Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar) |
| 09/30/2004 | WO2004073603A3 Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity |
| 09/30/2004 | WO2004065578A3 Microparticles comprising polynucleotide adsorbed on the surface of or entrapped within the microparticles |
| 09/30/2004 | WO2004062651A8 Pharmaceutical aerosol composition |
| 09/30/2004 | WO2004060295A3 Methods of inducing and maintaining immune tolerance |
| 09/30/2004 | WO2004052920A3 Conversion of apoptotic proteins |
| 09/30/2004 | WO2004043286A3 Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen |
| 09/30/2004 | WO2004035618A3 Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof |
| 09/30/2004 | WO2004030519A3 Thymic atrophy |
| 09/30/2004 | WO2004029092A3 Antibody for adcc and inducing cytokine production |
| 09/30/2004 | WO2004028564A3 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 09/30/2004 | WO2003102021A3 Cotton rat lung cells for virus culture |
| 09/30/2004 | WO2003099860A3 Immunogenic composition and peptide sequences for prevention and treatment of an hsv condition |
| 09/30/2004 | WO2003080105A9 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof |
| 09/30/2004 | WO2003073097A3 Methods for isolating ligands e.g. t cell epitopes |
| 09/30/2004 | WO2003072740A3 Novel type-1 cytokine receptor glm-r |
| 09/30/2004 | WO2003068197A8 Method for systemic drug delivery through the nail |
| 09/30/2004 | WO2003049703A3 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 09/30/2004 | WO2003048328A9 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| 09/30/2004 | WO2003039491A3 Novel isoforms of vascular endothelial cell growth inhibitor |
| 09/30/2004 | WO2003031930A3 A phosphatase associated with metastasis |
| 09/30/2004 | US20040194155 Comprises hepatitis b viral nucleotide sequences coding mutant reverse transcriptase for use in developing antibodies to prevent or treat hepatitis viral infection; immunotherapy; |
| 09/30/2004 | US20040192903 Comprises chromosomal regoin which codes pathogenicity islands (PAIs) for use in developing antibodies to detect and prevent bacterial infection; bactericides |
| 09/30/2004 | US20040192900 Calicheamicin derivative-carrier conjugates |
| 09/30/2004 | US20040192898 Anti-abeta antibodies |
| 09/30/2004 | US20040192654 use of nucleoside analogues as an effective treatment for acute or chronic myelogenous leukemia; (-)- beta -L-Dioxolane-Cytidine ( beta -L-oddC); (-)- beta -Dioxolane-5-fluoro-Cytidine (5-FddC) |
| 09/30/2004 | US20040192631 for immune response against cancer cells; comprises a DNA construct operably encoding a cancer-associated Inhibitor of Apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor; administering the tumor growth inhibitor |
| 09/30/2004 | US20040192596 Therapeutic fibrin-derived peptides and uses thereof |
| 09/30/2004 | US20040192588 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 09/30/2004 | US20040191886 Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins |
| 09/30/2004 | US20040191866 Attenuated microorganisms for the treatment of infection |
| 09/30/2004 | US20040191847 Kit for diagnosing gaucher disease in humans and animals |
| 09/30/2004 | US20040191843 Cytotoxic mixture comprising polypeptides for treatment and prevention of cell proliferfative disorders |
| 09/30/2004 | US20040191840 Using immunoglobulins to inactivate viricidal and antitumor activities of huma n type interferon for preventing autoimmunity and graft rejection; immunosuppressants |
| 09/30/2004 | US20040191818 Compositions and methods for diagnosing and treating autoimmune diseases |
| 09/30/2004 | US20040191767 Comprises nucleotide sequences coding hepatitis core protein fusion for generating vaccine to prevent infcetion and treat liver dysfunction; gene therapy and cell-mediated immune response |
| 09/30/2004 | US20040191763 HBV mutations associated with reduced susceptibility to adefovir |
| 09/30/2004 | US20040191761 Modified adenoviral E1A constructs and methods of use thereof |
| 09/30/2004 | US20040191328 Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia |
| 09/30/2004 | US20040191320 Pulmonary formulation |
| 09/30/2004 | US20040191304 Vaccine adjuvant properties of lipsomes formed at elevated temperatures from the polar chloroform extractable lipids from mycobacterium bovis bacillus calmette-guerin |
| 09/30/2004 | US20040191273 Methods and compositions for obtaining disease protection for economically important animals |
| 09/30/2004 | US20040191272 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 09/30/2004 | US20040191270 Vaccine compositions |
| 09/30/2004 | US20040191269 Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods |
| 09/30/2004 | US20040191268 Isolated, synthetic or recombinant nonapeptide of a minor Histocompatability antigen HA-1 comprising the sequence valine-leucine-X-aspartic acid-aspartic acid-leucine-leucine-glutamic acid-alanine wherein X is arginine or histidine; bone marrow transplants; graft versus host disease; leukemia |
| 09/30/2004 | US20040191267 Neisseria spp. polypeptide, nucleic acid sequence and uses thereof |
| 09/30/2004 | US20040191266 Killed cells of Mycobacterium avium as immunogens and mineral oil; immunocontraceptive vaccines such as gonadotropin releasing hormone (GnRH) |
| 09/30/2004 | US20040191264 Synthetic vaccine agents |
| 09/30/2004 | US20040191263 Enteral compositions for the prevention and/or treatment of sepsis |
| 09/30/2004 | US20040191262 Isolated and purified antigen expressed by wild-type Ehrlichia risticii strain; vaccines |
| 09/30/2004 | US20040191253 Treating vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft; administering anti-platelet derived growth factor receptor antibody with heparin |
| 09/30/2004 | US20040191248 Antibody therapy |
| 09/30/2004 | US20040191247 Use of il-18 inhibitors for treating or preventing cns injuries |
| 09/30/2004 | US20040191246 Process for in vivo treatment of specific biological targets in bodily fluid |
| 09/30/2004 | US20040191243 Solid may comprise excipient of mannitol, polysorbate, succinate, citrate, Tris, phosphate, trehalose, amino acids, polyoxyethylene glyclol, albumins, sucrose, lactose, maltose, and/or sorbitol; kits; monoclonal antibodies; freeze drying |
| 09/30/2004 | US20040191242 Method for producing a vaccine |